Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Feb 18, 2022 3:25pm
118 Views
Post# 34443144

RE:RE:Wow

RE:RE:WowThese genetic test look for mutations related to cancer, they cannot tell you the expression level of a normal protein like sortilin. What they can do, in some cases, is to avoid a given chemotherapy drug, or chose one that will work. Here in Quebec it is available for free for pediatric cancers. Maybe some adults can also have it for free. But you can pay to have it from a private company, but you also need a biopsy. To me the best way to do a personalized treatment with TH19P01 based PDC would be to develop an imaging PDC for PET scans which would be TH19P01-DOTA-Ga68. I know I said it many times here, but it seems so obvious. It does not only allow to see if sortilin is overxpressed.It allows to see the PDC binding with the tumors and also distribution in other organs. If they achieve proof of concept, they need to develop that. It would be easy and quick. They have all the building blocks, and Gallium 68 has a track record of use in humans. So its toxicity is well known, and with the newest PET scanners, the needed injected dose to get good images is much lower than before.


Wino115 wrote:
By the way, in the KOL transcript for the Ovarian Endo talk I posted about, the doctor said that it's now pretty standard at Mass General that they run a tumor sample genetic test and know all the various genetic expression levels prior to talking about any treatment options. She made it sound like that was more or less standard now at any cancer oriented hospital setting. I may be wrong, but wouldn't that be where you'd find Sort1 levels too, as opposed to staining?


<< Previous
Bullboard Posts
Next >>